Prevention of infection following severe acute pancreatitis

Current Opinion in Critical Care

Volumn 13, Issue 4, 2007, Pages 416-420

  Tellado, Jose M ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Acute pancreatitis; Antibiotic prophylaxis; Enteral nutrition; Probiotics; Scoring systems

Indexed keywords

ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CIPROFLOXACIN; ERTAPENEM; FLEROXACIN; FLUCONAZOLE; MOXIFLOXACIN; QUINOLONE DERIVATIVE; TROVAFLOXACIN;

ACUTE PANCREATITIS; ANTIBIOTIC PROPHYLAXIS; BACTERIAL OVERGROWTH; DISEASE COURSE; DISEASE SEVERITY; DRUG DISTRIBUTION; DRUG PENETRATION; HUMAN; INFECTION PREVENTION; NONHUMAN; PANCREAS; PANCREAS DISEASE; PANCREAS INFECTION; PANCREAS NECROSIS; PRACTICE GUIDELINE; REVIEW; SCORING SYSTEM;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; HUMANS; INFECTION CONTROL; PANCREATITIS; RANDOMIZED CONTROLLED TRIALS; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 34347336648     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e32826388b2     Document Type: Review

References (34)

1. Gocmen E, Klc YA, Yoldas O, et al. Comparison and validation of scoring systems in a cohort of patients treated for biliary acute pancreatitis. Pancreas 2007; 34:66-69.
2. Keskinen P, Leppaniemi A, Pettila V, et al. Intra-abdominal pressure in severe acute pancreatitis. World J Emerg Surg 2007; 2:2 (Open-access article). Data from 59 patients with SAP treated in the ICU of Helsinki University Hospital are presented. Intra-abdominal pressure was measured by the intravesical route. The maximal IAP was 7-14, 15-18, 19-24 and 25-33 mmHg and the hospital mortality rates were 10%, 12.5%, 22.2% and 50% in groups 1-4, respectively. Frequent measurement of IAP during ICU admission may allow early recognition of the abdominal compartment syndrome and those patients who may benefit from decompressive laparotomy.
3. Rosas JM, Soto SN, Aracil JS, et al. Intra-abdominal pressure as a marker of severity in acute pancreatitis. Surgery 2007; 141:173-178. The authors studied the utility of IAP as a marker of illness severity in a cohort of 45 patients admitted to the ICU of Parc Tauli Hospital (Sabadell, Spain) because of acute pancreatitis. Maximum IAP exhibited a significant relationship with the computed tomography severity index and was significantly greater in patients who died.
4. Rahman SH, Menon KV, Holmfield JH, et al. Serum macrophage migration inhibitory factor is an early marker of pancreatic necrosis in acute pancreatitis. Ann Surg 2007; 245:282-289.
5. Matsuda N, Nishihira J, Takahashi Y, et al. Role of macrophage migration inhibitory factor in acute lung injury in mice with acute pancreatitis complicated by endotoxemia. Am J Respir Cell Mol Biol 2006; 35:198-205.
6. De Waele JJ, Delrue L, Hoste EA, et al. Extrapancreatic inflammation on abdominal computed tomography as an early predictor of disease severity in acute pancreatitis: evaluation of a new scoring system. Pancreas 2007; 34:185-190. A novel scoring system based on early signs of systemic inflammation (ascitis, pleural effusion and retroperitoneal inflammation) on computed tomography (the EPIC score) was developed at the Gent University Hospital, which may complement the Balthazar score. An EPIC score of 4 or more had a 100% sensitivity and 70.8% specificity for predicting severe pancreatitis. The EPIC score allows accurate estimation of disease severity and mortality within 24 h of admission.
7. Arvanitakis M, Koustiani G, Gantzarou A, et al. Staging of severity and prognosis of acute pancreatitis by computed tomography and magnetic resonance imaging: a comparative study. Dig Liver Dis 2007; 39:473-482.
8. Stimac D, Miletic D, Radic M, et al. The role of nonenhanced magnetic resonance imaging in the early assessment of acute pancreatitis. Am J Gastroenterol 2007; 102:997-1004.
9. Mofidi R, Duff MD, Madhavan KK, et al. Identification of severe acute pancreatitis using an artificial neural network. Surgery 2007; 141:59-66. This study, conducted at the Department Clinical and Surgical Sciences (University of Edinburgh), validates a novel approach to constructing scoring systems in acute pancreatitis by means of artificial neural network analysis. A total of 664 patients with acute pancreatitis were identified, of whom 27.3% had SAP. The new score was more accurate at predicting progression and the appearance of multiple organ failure (P<0.01).
10. Bassi C, Pederzoli P, Vesentini S, et al. Behavior of antibiotics during human necrotizing pancreatitis. Antimicrob Agents Chemother 1994; 38:830-836.
11. Buchler M, Malfertheiner P, Frieb H, et al. Human pancreatic tissue concentration of bactericidal antibiotics. Gastroenterology 1992; 103:1902-1908.
12. Adam U, Herms S, Werner U, et al. The penetration of ciprofloxacin into human pancreatic and peripancreatic necroses in acute necrotizing pancreatitis. Infection 2001; 29:326-331.
13. Shrikhande S, Friess H, Issenegger C, et al. Fluconazole penetration into the pancreas. Antimicrob Agents Chemother 2000; 44:2569-2571.
14. Wacke R, Forster S, Adam U, et al. Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose. J Antimicrob Chemother 2006; 58:994-999. This study examined penetration of moxifloxacin (a fourth generation fluoroquinolone) into pancreas in 60 patients undergoing elective pancreas resection, who received a single oral or intravenous dose of 400 mg as perioperative antimicrobial prophylaxis. The mean tissue : plasma ratios varied from 1.8±0.6 to 2.6±1.2.
15. Wittau M, Wagner E, Kaever V, et al. Intraabdominal tissue concentration of ertapenem. J Antimicrob Chemother 2006; 57:312-316. Penetration of ertapenem (a class I carbapenem) into pancreas was tested in 13 patients undergoing elective pancreatic surgery receiving 1 g (intravenous) as surgical prophylaxis. The mean tissue : plasma ratios were 0.19 (colon) and 0.095 (pancreas).
16. Wang Y, Ye F, Jeong EK, et al. Noninvasive visualization of pharmacokinetics, biodistribution and tumor targeting of poly[N-(2- hydroxypropyl)methacrylamide] in mice using contrast enhanced MRI. Pharm Res 2007 [Epub ahead of print].
17. Fischman AJ, Babich JW, Bonab AA, et al. Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography. Antimicrob Agents Chemother 1998; 42:2048-2054.
18. Pederzoli P, Bassi C, Vesentini S, Campedelli A. A randomized multicenter clinical trial of antibiotic prophylaxis of septic complications in acute necrotizing pancreatitis with imipenem. Surg Gynecol Obstet 1993; 176:480-483.
19. Barie PS. A critical review of antibiotic prophylaxis in severe acute pancreatitis. Am J Surg 1996; 172 (6A):38S-43S.
20. Isenmann R, Runzi M, Kron M, et al., for the German Antibiotics in Severe Acute Pancreatitis Study Group. Prophylactic antibiotic treatment in patients with predicted severe acute pancreatitis: a placebo-controlled, double-blind trial. Gastroenterology 2004; 126:997-1004.
21. Dellinger EP, Tellado JM, Soto NE, et al. Early antibiotic treatment for severe acute necrotizing pancreatitis: a randomized, double-blind, placebo-controlled study. Ann Surg 2007; 245:674-683. This multicentre, prospective, double-blind, placebo-controlled randomized study was conducted in 32 centres within North America and Europe in patients with confirmed necrotizing pancreatitis. It compared meropenem (n = 50, 1 g intravenously every 8 h) with placebo (n = 50) within 5 days of the onset of symptoms for 7-21 days. The primary end-point was development of pancreatic or peripancreatic infection within 42 days after randomization. Pancreatic or peripancreatic infections developed in 18% of patients in the meropenem group as compared with 12% of those in the placebo group (P = 0.401). The authors concluded that this study did not support early prophylactic antimicrobial use in patients with severe acute necrotizing pancreatitis.
22. Eggimann P, Jamdar S, Siriwardena AK. Pro/con debate: antifungal prophylaxis is important to prevent fungal infection in patients with acute necrotizing pancreatitis receiving broad-spectrum antibiotics. Crit Care 2006; 10:229.
23. Berzin TM, Rocha FG, Whang EE, et al. Prevalence of primary fungal infections in necrotizing pancreatitis. Pancreatology 2007; 7:63-66. The aim of this study, conducted at the Department of Medicine, Brigham and Women's Hospital (Boston, Massachusetts, USA), was to determine the prevalence of primary fungal infections in SAP under broad-spectrum antibiotic regimens. Sixty-four cases of SAP out of 689 consecutive acute pancreatitis cases did not acquire a primary pancreatic fungal infection. The authors indicated that limited use and short duration of carbapenem therapy may be factors that contributed to the absence of primary fungal infections.
24. Mazaki T, Ishii Y, Takayama T. Meta-analysis of prophylactic antibiotic use in acute necrotizing pancreatitis. Br J Surg 2006; 93:674-684.
25. Villatoro E, Bassi C, Larvin M. Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis. Cochrane Database Syst Rev 2006, 4:CD002941.
26. Zandstra DF, van Saene HK. Chris Stoutenbeek and selective digestive decontamination. Intensive Care Med 2007; 33:207-208.
27. Luiten EJ, Hop WC, Lange JF, Bruining HA. Controlled clinical trial of selective decontamination for the treatment of severe acute pancreatitis. Ann Surg 1995; 222:57-65.
28. McClave SA, Chang WK, Dhaliwal R, Heyland DK. Nutrition support in acute pancreatitis: a systematic review of the literature. J Parenter Enteral Nutr 2006; 30:143-156. This is a review of 27 prospective randomized trials conducted in adult patients with acute pancreatitis that evaluated interventions with nutritional therapy. A meta-analysis of seven trials showed use of enteral nutrition to be associated with significant reductions in infectious morbidity and hospital length of stay, and a trend toward reduced organ failure, with no effect on mortality when compared with use of parenteral nutrition. Insufficient data exist to determine whether enteral nutrition improves outcome over standard therapy (no artificial nutrition support) in patients admitted for acute pancreatitis. Enteral nutrition has become the new 'gold standard' of nutritional therapy in SAP.
29. Eckerwall GE, Axelsson JB, Andersson RG. Early nasogastric feeding in predicted severe acute pancreatitis: A clinical, randomized study. Ann Surg 2006; 244:959-965.
30. Olah A, Belagyi T, Issekutz A, et al. Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis. Br J Surg 2002; 89:1103-1107.
31. Timmerman HM, Koning CJ, Mulder L, et al. Monostrain, multistrain and multispecies probiotics - A comparison of functionality and efficacy. Int J Food Microbiol 2004; 96:219-233.
32. Besselink MG, Timmerman HM, Buskens E, et al., Dutch Acute Pancreatitis Study Group. Probiotic prophylaxis in patients with predicted severe acute pancreatitis (PROPATRIA): design and rationale of a double-blind, placebo-controlled randomised multicenter trial (ISRCTN38327949). BMC Surg 2004; 4:12 (Open-access article).
33. van Minnen LP, Timmerman HM, Lutgendorff F, et al. Modification of intestinal flora with multispecies probiotics reduces bacterial translocation and improves clinical course in a rat model of acute pancreatitis. Surgery 2007; 141:470-480. The investigators showed that probiotics reduced duodenal bacterial overgrowth of potential pathogens, resulting in reduced bacterial translocation to extraintestinal sites, including the pancreas. This preclinical study supports the launch of a phase II (security and efficacy) trial in patients aiming to prevent necrotic tissue infection in SAP.
34. de Madaria E, Martinez J, Lozano B, et al. Detection and identification of bacterial DNA in serum from patients with acute pancreatitis. Gut 2005; 54:1293-1297.